NICE(UK): Acalabrutinib plus venetoclax can be used as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. It can only be used: i) without obinutuzumab, and ii)… read more.
An analysis of 103 European cities’ 2030 climate neutral plans (including 22 capital cities) shows that municipalities are planning to rely on carbon removal to compensate for about… read more.
A real-time prescription benefit (RTPB) tool did not change overall prescription fill rates but did increase fill rates for high-cost medications, according to a post hoc analysis of… read more.
Physicians born outside the United States account for close to half of the internal medicine workforce in the US and shoulder a disproportionate share of care for underserved… read more.
As temperatures continue to soar and amber heat-health alerts are issued across England, warnings are reaching the public but still failing to change behaviour. A new investigation by the United… read more.
NICE(UK): Acalabrutinib plus bendamustine and rituximab can be used, within its marketing authorisation, as an option for untreated mantle cell lymphoma in adults who are not eligible for… read more.
Epilepsy remains a major public health challenge, but its burden is changing in ways that reveal health inequalities. Global Burden of Disease Study 2021 (GBD 2021) data indicate… read more.
NICE(UK): Donidalorsen can be used as an option to prevent recurrent attacks of hereditary angioedema (HAE) in people 12 years and over, only if: i) they have 2 or more… read more.
The results show a need for nuanced communication between doctors and patients. “Always finish your antibiotics” is no longer considered medical best practice for all conditions. Surprised? You’re… read more.
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or… read more.
Ultragenyx Pharmaceutical announced that the FDA granted accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX 401, in adult and pediatric patients eight years and older with… read more.
The study found that workplace culture and day-to-day working conditions were among the strongest factors influencing whether nurses in the later stages of their careers chose to stay in the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
